Axa S.A. Has $7.04 Million Stock Position in Moderna, Inc. (NASDAQ:MRNA)

AXA S.A. decreased its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 18.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 169,182 shares of the company's stock after selling 38,456 shares during the quarter. AXA S.A.'s holdings in Moderna were worth $7,035,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB increased its holdings in Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after purchasing an additional 587 shares during the last quarter. Compass Planning Associates Inc acquired a new stake in Moderna in the fourth quarter valued at $37,000. Venturi Wealth Management LLC boosted its stake in Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after acquiring an additional 664 shares during the last quarter. Crowley Wealth Management Inc. acquired a new position in Moderna during the 4th quarter worth $41,000. Finally, Itau Unibanco Holding S.A. increased its position in shares of Moderna by 51.2% in the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock worth $42,000 after purchasing an additional 343 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. UBS Group decreased their price target on Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Citigroup assumed coverage on Moderna in a report on Thursday, March 13th. They issued a "neutral" rating and a $40.00 price target for the company. Evercore ISI reduced their price objective on Moderna from $50.00 to $32.00 and set an "in-line" rating on the stock in a research note on Friday, May 2nd. Barclays lowered their target price on shares of Moderna from $45.00 to $40.00 and set an "equal weight" rating for the company in a research note on Friday, May 2nd. Finally, Bank of America decreased their price target on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a report on Tuesday, February 11th. Four investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Moderna presently has a consensus rating of "Hold" and an average price target of $53.95.

Moderna Stock Performance

Shares of MRNA stock traded down $0.13 during mid-day trading on Friday, hitting $24.25. 7,118,541 shares of the stock traded hands, compared to its average volume of 7,578,313. Moderna, Inc. has a twelve month low of $23.15 and a twelve month high of $170.47. The company's 50-day simple moving average is $29.01 and its 200-day simple moving average is $36.78. The firm has a market cap of $9.38 billion, a price-to-earnings ratio of -2.61 and a beta of 1.99.

Moderna (NASDAQ:MRNA - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.92) by $0.40. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. The firm had revenue of $108.00 million for the quarter, compared to analyst estimates of $130.35 million. During the same period in the previous year, the company earned ($3.07) earnings per share. Moderna's revenue was down 35.3% compared to the same quarter last year. Analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.